(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 10.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.09%.
Immunocore Holdings's revenue in 2026 is $430,775,000.On average, 14 Wall Street analysts forecast IMCR's revenue for 2026 to be $23,773,821,552, with the lowest IMCR revenue forecast at $22,321,045,566, and the highest IMCR revenue forecast at $25,312,085,242. On average, 14 Wall Street analysts forecast IMCR's revenue for 2027 to be $25,383,668,319, with the lowest IMCR revenue forecast at $17,573,903,051, and the highest IMCR revenue forecast at $32,493,052,396.
In 2028, IMCR is forecast to generate $30,177,674,576 in revenue, with the lowest revenue forecast at $15,622,620,453 and the highest revenue forecast at $45,719,442,200.